TWI372620B - Treatment of autoimmune diseases - Google Patents
Treatment of autoimmune diseasesInfo
- Publication number
- TWI372620B TWI372620B TW099117063A TW99117063A TWI372620B TW I372620 B TWI372620 B TW I372620B TW 099117063 A TW099117063 A TW 099117063A TW 99117063 A TW99117063 A TW 99117063A TW I372620 B TWI372620 B TW I372620B
- Authority
- TW
- Taiwan
- Prior art keywords
- autoimmune diseases
- treatment
- neuritis
- uveitis
- invention describes
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 206010029240 Neuritis Diseases 0.000 abstract 2
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 150000001414 amino alcohols Chemical class 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71599005P | 2005-09-09 | 2005-09-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201034659A TW201034659A (en) | 2010-10-01 |
| TWI372620B true TWI372620B (en) | 2012-09-21 |
Family
ID=37056992
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095133326A TWI376223B (en) | 2005-09-09 | 2006-09-08 | Treatment of autoimmune diseases |
| TW099117063A TWI372620B (en) | 2005-09-09 | 2006-09-08 | Treatment of autoimmune diseases |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095133326A TWI376223B (en) | 2005-09-09 | 2006-09-08 | Treatment of autoimmune diseases |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20080200438A1 (zh) |
| EP (2) | EP1926483B1 (zh) |
| JP (4) | JP5244598B2 (zh) |
| KR (3) | KR20140117704A (zh) |
| CN (1) | CN101257899B (zh) |
| AT (1) | ATE489948T1 (zh) |
| AU (2) | AU2006289100B2 (zh) |
| BR (1) | BRPI0615906A2 (zh) |
| CA (2) | CA2820510A1 (zh) |
| CY (1) | CY1111285T1 (zh) |
| DE (1) | DE602006018629D1 (zh) |
| DK (2) | DK1926483T3 (zh) |
| ES (2) | ES2357426T3 (zh) |
| HK (1) | HK1149906A1 (zh) |
| IL (2) | IL189665A (zh) |
| JO (1) | JO2655B1 (zh) |
| MA (1) | MA29787B1 (zh) |
| MX (1) | MX2008003170A (zh) |
| NO (1) | NO20081727L (zh) |
| NZ (2) | NZ566137A (zh) |
| PL (2) | PL1926483T3 (zh) |
| PT (2) | PT2295049E (zh) |
| RU (2) | RU2493840C2 (zh) |
| SG (1) | SG165364A1 (zh) |
| SI (2) | SI1926483T1 (zh) |
| TN (1) | TNSN08103A1 (zh) |
| TW (2) | TWI376223B (zh) |
| WO (1) | WO2007028821A2 (zh) |
| ZA (1) | ZA200801694B (zh) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1772145B1 (en) * | 2004-07-16 | 2011-03-23 | Kyorin Pharmaceutical Co., Ltd. | Method of effectively using medicine and method concerning prevention of side effect |
| ES2563034T3 (es) | 2004-10-12 | 2016-03-10 | Kyorin Pharmaceutical Co., Ltd. | Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol e hidratos del mismo, e intermedios para la producción de los mismos |
| ES2385580T3 (es) * | 2005-10-07 | 2012-07-26 | Kyorin Pharmaceutical Co., Ltd. | Agente terapéutico para enfermedades hepáticas que contiene un derivado de 2-amino-1,3-propanodiol como ingrediente activo |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| RU2430925C2 (ru) * | 2006-08-08 | 2011-10-10 | Киорин Фармасьютикал Ко., Лтд. | Производное аминофосфата и модулятор рецептора s1p, содержащий его в качестве активного ингредиента |
| US8273748B2 (en) * | 2006-08-08 | 2012-09-25 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative and immunosuppresive agent having same as an active ingredient |
| US20100093745A1 (en) * | 2007-02-13 | 2010-04-15 | Kazuhiko Kuriyama | Therapeutic agent or prophylactic agent for demyelinating disease comprising amino alcohol derivative as active ingredient |
| US8476305B2 (en) | 2008-02-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient |
| EP2305305A4 (en) * | 2008-05-20 | 2013-02-13 | Kyorin Seiyaku Kk | INDUCTION / MAINTENANCE TRANSMITTER |
| WO2010020609A1 (en) * | 2008-08-18 | 2010-02-25 | Novartis Ag | Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies |
| BR112012028248A2 (pt) * | 2010-05-06 | 2016-08-02 | Novartis Ag | derivados de sulfeto de diarila, seu uso, e kit |
| EA201201514A1 (ru) * | 2010-05-06 | 2013-05-30 | Новартис Аг | Лечение аутоиммунных заболеваний |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5141421A (en) * | 1991-12-17 | 1992-08-25 | Carrier Corporation | Nested coupling mechanism for scroll machines |
| DE4428835A1 (de) * | 1994-08-01 | 1996-02-08 | Schering Ag | Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| PT990440E (pt) * | 1997-02-27 | 2009-02-05 | Novartis Ag | Composição farmacêutica compreendendo 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol, uma lecitina e um sacárido |
| CN1329372C (zh) * | 2001-09-27 | 2007-08-01 | 杏林制药株式会社 | 二芳基硫醚衍生物及其加成盐和免疫抑制剂 |
| JP4152884B2 (ja) * | 2001-09-27 | 2008-09-17 | 杏林製薬株式会社 | ジアリールエーテル誘導体とその付加塩及び免疫抑制剤 |
| CA2498944C (en) * | 2002-09-19 | 2011-05-17 | Yasushi Kohno | Amino alcohol derivatives, salts thereof and immunosuppressive agents |
| RU2478378C2 (ru) * | 2002-09-24 | 2013-04-10 | Новартис Аг | Органические соединения |
| ES2355233T3 (es) * | 2002-09-28 | 2011-03-24 | Mcneil-Ppc, Inc. | Formas de dosificación de liberación modificada con dos núcleos y una abertura. |
| EP2172472B1 (en) * | 2003-02-18 | 2012-12-26 | Kyorin Pharmaceutical Co., Ltd. | Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor |
| PE20150676A1 (es) * | 2003-04-08 | 2015-05-17 | Novartis Ag | Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar |
| TW200505416A (en) * | 2003-08-12 | 2005-02-16 | Mitsubishi Pharma Corp | Bi-aryl compound having immunosuppressive activity |
| ATE449069T1 (de) * | 2003-08-28 | 2009-12-15 | Novartis Pharma Gmbh | Aminopropanolderivate |
| EP1772145B1 (en) * | 2004-07-16 | 2011-03-23 | Kyorin Pharmaceutical Co., Ltd. | Method of effectively using medicine and method concerning prevention of side effect |
| KR20070085465A (ko) * | 2004-11-29 | 2007-08-27 | 노파르티스 아게 | Ｓ１ｐ 수용체 효능제의 투여 용법 |
| GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
-
2006
- 2006-09-07 ES ES06793341T patent/ES2357426T3/es active Active
- 2006-09-07 JP JP2008529636A patent/JP5244598B2/ja active Active
- 2006-09-07 DK DK06793341.6T patent/DK1926483T3/da active
- 2006-09-07 SG SG201006580-3A patent/SG165364A1/en unknown
- 2006-09-07 PL PL06793341T patent/PL1926483T3/pl unknown
- 2006-09-07 EP EP06793341A patent/EP1926483B1/en active Active
- 2006-09-07 US US12/065,096 patent/US20080200438A1/en not_active Abandoned
- 2006-09-07 PL PL10174280T patent/PL2295049T3/pl unknown
- 2006-09-07 CN CN2006800328984A patent/CN101257899B/zh not_active Expired - Fee Related
- 2006-09-07 JO JO2006298A patent/JO2655B1/en active
- 2006-09-07 RU RU2011111117/15A patent/RU2493840C2/ru not_active IP Right Cessation
- 2006-09-07 KR KR1020147026128A patent/KR20140117704A/ko not_active Application Discontinuation
- 2006-09-07 AT AT06793341T patent/ATE489948T1/de active
- 2006-09-07 DE DE602006018629T patent/DE602006018629D1/de active Active
- 2006-09-07 SI SI200630937T patent/SI1926483T1/sl unknown
- 2006-09-07 DK DK10174280.7T patent/DK2295049T3/en active
- 2006-09-07 EP EP10174280.7A patent/EP2295049B1/en active Active
- 2006-09-07 CA CA2820510A patent/CA2820510A1/en not_active Abandoned
- 2006-09-07 ES ES10174280.7T patent/ES2529724T3/es active Active
- 2006-09-07 AU AU2006289100A patent/AU2006289100B2/en not_active Ceased
- 2006-09-07 PT PT10174280T patent/PT2295049E/pt unknown
- 2006-09-07 WO PCT/EP2006/066150 patent/WO2007028821A2/en active Application Filing
- 2006-09-07 PT PT06793341T patent/PT1926483E/pt unknown
- 2006-09-07 KR KR1020147001496A patent/KR101476591B1/ko not_active IP Right Cessation
- 2006-09-07 SI SI200631889T patent/SI2295049T1/sl unknown
- 2006-09-07 BR BRPI0615906-0A patent/BRPI0615906A2/pt not_active IP Right Cessation
- 2006-09-07 NZ NZ566137A patent/NZ566137A/en not_active IP Right Cessation
- 2006-09-07 CA CA2620554A patent/CA2620554C/en not_active Expired - Fee Related
- 2006-09-07 MX MX2008003170A patent/MX2008003170A/es active IP Right Grant
- 2006-09-07 RU RU2008113187/15A patent/RU2424795C2/ru not_active IP Right Cessation
- 2006-09-07 NZ NZ588372A patent/NZ588372A/en not_active IP Right Cessation
- 2006-09-08 TW TW095133326A patent/TWI376223B/zh active
- 2006-09-08 TW TW099117063A patent/TWI372620B/zh not_active IP Right Cessation
-
2008
- 2008-02-21 ZA ZA200801694A patent/ZA200801694B/xx unknown
- 2008-02-21 IL IL189665A patent/IL189665A/en not_active IP Right Cessation
- 2008-03-06 TN TNP2008000103A patent/TNSN08103A1/en unknown
- 2008-03-17 MA MA30758A patent/MA29787B1/fr unknown
- 2008-04-07 NO NO20081727A patent/NO20081727L/no not_active Application Discontinuation
- 2008-04-08 KR KR1020087008413A patent/KR101476451B1/ko not_active IP Right Cessation
-
2010
- 2010-09-21 AU AU2010224355A patent/AU2010224355B2/en not_active Ceased
-
2011
- 2011-03-01 CY CY20111100242T patent/CY1111285T1/el unknown
- 2011-04-27 HK HK11104200A patent/HK1149906A1/zh unknown
-
2012
- 2012-10-17 JP JP2012230044A patent/JP6077265B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-23 IL IL233328A patent/IL233328A0/en unknown
- 2014-09-29 JP JP2014199069A patent/JP2015025002A/ja not_active Withdrawn
-
2016
- 2016-09-30 JP JP2016193400A patent/JP2017019854A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI372620B (en) | Treatment of autoimmune diseases | |
| TW200509892A (en) | Novel aminobenzophenone compounds | |
| EP1841426A4 (en) | TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| EP1673078A4 (en) | BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| WO2006058868A8 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| WO2006078576A3 (en) | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease | |
| PL1910338T3 (pl) | Związki heterotetracykliczne jako mimetyki TPO | |
| UA90698C2 (en) | Triazole substituted aminobenzophenone compounds | |
| TW200806325A (en) | Therapeutic uses of inhibitors of RTP801 | |
| MX2008002166A (es) | Compuestos y composiciones como mimeticos de trombopoietina (tpo). | |
| MX2008007808A (es) | Analogos de rifamicina y usos de ellos. | |
| TW200635597A (en) | Substituted pteridines for the treatment of inflammatory diseases | |
| WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| MX2011012015A (es) | Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. | |
| WO2007058862A3 (en) | Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
| TW200633711A (en) | Substituted pteridines for the treatment of inflammatory diseases | |
| TW200639155A (en) | Thiazolidinones, their production and use as pharmaceutical agents | |
| MX2010000956A (es) | Derivados de isoftalamida que inhiben actividad de beta-secretasa. | |
| BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
| WO2007019080A3 (en) | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease | |
| IL181713A0 (en) | Use of il-17f for the treatment and/or prevention of neurological diseases | |
| TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors | |
| CY1116051T1 (el) | Θεραπεια αυτοανοσων ασθενειων | |
| TW200628453A (en) | Triazole substituted aminobenzophenone compounds | |
| BRPI0402756A (pt) | método para o tratamento de distúrbios cognitivos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |